AngioDynamics Inc (ANGO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AngioDynamics Inc stock (ANGO) is currently trading at $10.63. AngioDynamics Inc PS ratio (Price-to-Sales) is 1.40. Analyst consensus price target for ANGO is $19.33. WallStSmart rates ANGO as Sell.
- ANGO PE ratio analysis and historical PE chart
- ANGO PS ratio (Price-to-Sales) history and trend
- ANGO intrinsic value — DCF, Graham Number, EPV models
- ANGO stock price prediction 2025 2026 2027 2028 2029 2030
- ANGO fair value vs current price
- ANGO insider transactions and insider buying
- Is ANGO undervalued or overvalued?
- AngioDynamics Inc financial analysis — revenue, earnings, cash flow
- ANGO Piotroski F-Score and Altman Z-Score
- ANGO analyst price target and Smart Rating
AngioDynamics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
AngioDynamics Inc (ANGO) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
AngioDynamics Inc (ANGO) Key Strengths (3)
96.55% of shares held by major funds and institutions
Good growth relative to its price
Paying $1.40 for every $1 of annual revenue
Supporting Valuation Data
AngioDynamics Inc (ANGO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Modest revenue growth at 9.00%
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
AngioDynamics Inc (ANGO) Detailed Analysis Report
Overall Assessment
This company scores 41/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., PEG Ratio, Price/Sales. Valuation metrics including PEG Ratio (1.41), Price/Sales (1.40) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (2.44) suggest expensive pricing. Growth concerns include Revenue Growth at 9.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -15.30%, Operating Margin at -3.14%, Profit Margin at -9.02%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -15.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ANGO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ANGO's Price-to-Sales ratio of 1.40x trades at a deep discount to its historical average of 3.03x (9th percentile). The current valuation is 90% below its historical high of 14.21x set in Jun 2006, and 37% above its historical low of 1.02x in Aug 2023.
Compare ANGO with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for AngioDynamics Inc (ANGO) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
AngioDynamics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 307M with 9% growth year-over-year. The company is currently unprofitable, posting a -9.0% profit margin.
Key Findings
Generating 4M in free cash flow and 5M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -9.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact AngioDynamics Inc.
Bottom Line
AngioDynamics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About AngioDynamics Inc(ANGO)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.